CRUK

The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.

The project aims to improve methods for general practitioners to diagnose cancer, lowering waiting times and reducing the burden of referrals. 

In support of the launch, researchers published a study demonstrating the test can help improve diagnosis of patients with unclear results from standard cytology methods.